Stock Analiz

Thermo Fisher Scientific Inc. (TMO) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Thermo Fisher Scientific’s revenue went from $18.3B in fiscal 2016 to $44.6B in fiscal 2025, growth of about 10.4% a year.

Net income in fiscal 2025 was $6.7B, a net margin of 15.0%; the best year in this period was 2021 with $7.7B.

Over the twelve months to September 26, 2026, revenue was $47.4B and net income $7.1B.

Free cash flow was $6.3B in fiscal 2025 and positive in 10 of the 10 years shown.

The diluted share count fell 5% over the period (buybacks).

Revenue, profit and cash flow by year

Revenue
2016: $18.3B162017: $20.9B172018: $24.4B182019: $25.5B192020: $32.2B202021: $39.2B212022: $44.9B222023: $42.9B232024: $42.9B242025: $44.6B25$44.6B
Net income
2016: $2.0B162017: $2.2B172018: $2.9B182019: $3.7B192020: $6.4B202021: $7.7B212022: $7.0B222023: $6.0B232024: $6.3B242025: $6.7B25$6.7B
Free cash flow
2016: $2.8B162017: $3.5B172018: $3.8B182019: $4.0B192020: $6.8B202021: $6.8B212022: $6.9B222023: $6.9B232024: $7.3B242025: $6.3B25$6.3B
EPS (diluted)
2016: $5.09162017: $5.59172018: $7.24182019: $9.17192020: $15.96202021: $19.46212022: $17.63222023: $15.45232024: $16.53242025: $17.7425$17.74

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$47.4B$44.6B$42.9B$42.9B$44.9B$39.2B$32.2B$25.5B$24.4B$20.9B$18.3B
Gross profit—————————$11.9B$10.1B
Operating income$8.5B$7.7B$7.3B$6.9B$8.4B$10.0B$7.8B$4.6B$3.8B$3.0B$2.5B
Net income$7.1B$6.7B$6.3B$6.0B$7.0B$7.7B$6.4B$3.7B$2.9B$2.2B$2.0B
EPS (diluted)$18.96$17.74$16.53$15.45$17.63$19.46$15.96$9.17$7.24$5.59$5.09
R&D$1.4B$1.4B$1.4B$1.3B$1.5B$1.4B$1.2B$1.0B$967M$887M$754M
Revenue growth—+3.9%+0.1%−4.6%+14.5%+21.7%+26.1%+4.9%+16.4%+14.5%+7.7%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$9.3B$7.8B$8.7B$8.4B$9.2B$9.3B$8.3B$5.0B$4.5B$4.0B$3.3B
Capital spending-$1.7B-$1.5B-$1.4B-$1.5B-$2.2B-$2.5B-$1.5B-$926M-$758M-$508M-$444M
Free cash flow$7.6B$6.3B$7.3B$6.9B$6.9B$6.8B$6.8B$4.0B$3.8B$3.5B$2.8B
Dividends paid$673M$636M$583M$523M$455M$395M$337M$297M$266M$237M$238M
Buybacks$4.0B$3.0B$4.0B$3.0B$3.0B$2.0B$1.5B$1.5B$500M$750M$1.2B
Stock-based pay$345M$310M$301M$278M$307M$230M$196M$181M$181M$159M$133M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$10.1B$5.6B$8.1B$8.5B$4.5B$10.3B$2.4B$2.1B$1.3B$786M
Debt—$40.9B$32.8B$36.4B$36.1B$36.3B$22.5B$18.5B$19.0B$21.2B$16.7B
Equity—$53.4B$49.6B$46.7B$44.0B$40.8B$34.5B$29.7B$27.6B$25.4B$21.5B
Total assets—$110.3B$97.3B$98.7B$97.2B$95.1B$69.1B$58.4B$56.2B$56.7B$45.9B
Shares (diluted)371M378M383M388M394M397M399M403M406M398M397M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin—————————57.1%55.0%
Operating margin17.9%17.4%17.1%16.0%18.7%25.6%24.2%18.0%15.5%14.1%13.5%
Net margin14.9%15.0%14.8%14.0%15.5%19.7%19.8%14.5%12.1%10.6%11.1%
FCF margin16.0%14.1%17.0%16.2%15.4%17.3%21.1%15.8%15.5%16.7%15.4%
ROIC—7.6%8.1%7.9%9.5%11.4%12.0%8.7%7.3%5.8%5.1%
ROE—12.6%12.8%12.8%15.8%18.9%18.5%12.4%10.7%8.8%9.4%

Frequently asked questions

What is Thermo Fisher Scientific’s annual revenue?

$44.6B in fiscal 2025 and $47.4B over the twelve months to September 26, 2026.

How much profit does Thermo Fisher Scientific make?

Net income was $6.7B in fiscal 2025 (net margin 15.0%).

Is Thermo Fisher Scientific’s revenue growing?

Yes: revenue rose 3.9% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.